SEARCH

SEARCH BY CITATION

References

  • 1
    Liang Y, Arakawa K, Martin T et al. JNJ-28431754/TA-7284, an SGLT inhibitor, lowers blood glucose and reduces body weight in obese and type 2 diabetic animal models, New Orleans, LA, Poster presented at the American Diabetes Association 69th Scientific Session, June 5–9, 2009.
  • 2
    Liang Y, Du F, Conway J et al. Effect of canagliflozin on renal threshold for glucose excretion in diabetic animals, San Diego, CA, Poster presented at the American Diabetes Association 71st Scientific Session, June 24–28, 2011.
  • 3
    Sha S, Devineni D, Ghosh A et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011; 13: 669672.
  • 4
    Sha S, Devineni D, Ghosh A et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, improved glucose control in subjects with type 2 diabetes and was well tolerated (Abstract #568-P). American Diabetes Association, 70th Scientific Sessions, 2010; Orlando, FL.
  • 5
    Urita Y, Ishihara S, Akimoto T et al. Seventy-five gram glucose tolerance test to assess carbohydrate malabsorption and small bowel bacterial overgrowth. World J Gastroenterol 2006; 12: 30923095.
  • 6
    Isaji M. SGLT2 inhibitors: molecular design and potential differences in effect. Kidney Int 2011; 79: S14S19.
  • 7
    Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010; 95: 3442.
  • 8
    Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin 2009; 25: 671681.
  • 9
    Rave K, Nosek L, Posner J, Heise T, Roggen K, van Hoogdalem EJ. Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes–results of a hyperglycaemic glucose clamp study. Nephrol Dial Transplant 2006; 21: 21662171.
  • 10
    Mogensen C. Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971; 28: 101109.